Author: JUNIPER POINT

Blacksmith Medicines and Collaborators to Present at the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

January 26, 2026
AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

January 8, 2026

Blacksmith Medicines and Collaborators to Present at the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)